David Martin PhD
Stock Analyst at Bloom Burton
(4.80)
# 552
Out of 5,116 analysts
243
Total ratings
52.7%
Success rate
18.2%
Average return
Main Sectors:
Stocks Rated by David Martin PhD
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals | Maintained: Buy | $21 | $16.14 | +30.11% | 36 | Nov 3, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $37 → $38 | $28.99 | +31.08% | 15 | Oct 28, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $19.56 | $9.37 | +108.80% | 7 | Oct 1, 2026 | |
| TSXV: CNVI Conavi Medical Corp. | Reiterated: Buy | $1.00 → $1.30 | $0.12 | +1,030.43% | 3 | Sep 29, 2026 | |
| TSX: DHT.UN DRI Healthcare Trust | Reiterated: Buy | $19.00 → $23.00 | $18.33 | +25.48% | 4 | Sep 23, 2026 | |
| XENE Xenon Pharmaceuticals | Reiterated: Buy | $74 → $71 | $37.62 | +88.73% | 9 | Sep 21, 2026 | |
| TSXV: RX BioSyent Inc. | Reiterated: Buy | $18.00 | $17.05 | +5.57% | 15 | Aug 24, 2026 | |
| TSX: MBX Microbix Biosystems Inc. | Reiterated: Buy | $0.40 | $0.29 | +37.93% | 14 | Aug 14, 2026 | |
| TSX: APTX Apotex Health Corp. | Reiterated: Buy | $40.00 | $33.61 | +19.01% | 3 | Aug 13, 2026 | |
| TSX: HLS HLS Therapeutics Inc. | Reiterated: Buy | $12.00 | $4.47 | +168.46% | 51 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6.00 → $6.50 | $4.84 | +34.30% | 14 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12.00 | $11.32 | +6.01% | 29 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.00 | $1.80 | +178.24% | 4 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.00 | $3.36 | +48.81% | 12 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8.38 → $4.00 | $0.43 | +841.18% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $11.12 | -19.06% | 6 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $25.30 | n/a | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $6.92 | $2.15 | n/a | 9 | Sep 8, 2020 |
Aurinia Pharmaceuticals
Nov 3, 2026
Maintained: Buy
Price Target: $21
Current: $16.14
Upside: +30.11%
Zymeworks
Oct 28, 2026
Reiterated: Buy
Price Target: $37 → $38
Current: $28.99
Upside: +31.08%
Eupraxia Pharmaceuticals Inc.
Oct 1, 2026
Reiterated: Buy
Price Target: $19.56
Current: $9.37
Upside: +108.80%
Conavi Medical Corp.
Sep 29, 2026
Reiterated: Buy
Price Target: $1.00 → $1.30
Current: $0.12
Upside: +1,030.43%
DRI Healthcare Trust
Sep 23, 2026
Reiterated: Buy
Price Target: $19.00 → $23.00
Current: $18.33
Upside: +25.48%
Xenon Pharmaceuticals
Sep 21, 2026
Reiterated: Buy
Price Target: $74 → $71
Current: $37.62
Upside: +88.73%
BioSyent Inc.
Aug 24, 2026
Reiterated: Buy
Price Target: $18.00
Current: $17.05
Upside: +5.57%
Microbix Biosystems Inc.
Aug 14, 2026
Reiterated: Buy
Price Target: $0.40
Current: $0.29
Upside: +37.93%
Apotex Health Corp.
Aug 13, 2026
Reiterated: Buy
Price Target: $40.00
Current: $33.61
Upside: +19.01%
HLS Therapeutics Inc.
Aug 13, 2026
Reiterated: Buy
Price Target: $12.00
Current: $4.47
Upside: +168.46%
Aug 12, 2026
Reiterated: Buy
Price Target: $6.00 → $6.50
Current: $4.84
Upside: +34.30%
Aug 7, 2026
Reiterated: Buy
Price Target: $12.00
Current: $11.32
Upside: +6.01%
Aug 5, 2026
Reiterated: Buy
Price Target: $5.00
Current: $1.80
Upside: +178.24%
Jul 31, 2026
Reiterated: Buy
Price Target: $5.00
Current: $3.36
Upside: +48.81%
Dec 11, 2025
Reiterated: Buy
Price Target: $8.38 → $4.00
Current: $0.43
Upside: +841.18%
Nov 19, 2025
Reiterated: Buy
Price Target: $9
Current: $11.12
Upside: -19.06%
Oct 21, 2025
Reiterated: Buy
Price Target: $14
Current: $25.30
Upside: n/a
Sep 8, 2020
Upgraded: Buy
Price Target: $6.92
Current: $2.15
Upside: n/a